AMETEK’s high-margin niche technology compounder offers attractive five-year upside, with Indicor integration and deleveraging the key catalysts against acquisition and cyclical risks.
Overview
AMETEK is a global industrial technology consolidator with more than 40 autonomous businesses organized into the Electronic Instruments Group and Electromechanical Group. EIG generated $4.92 billion of the latest completed fiscal year’s sales and EMG generated $2.48 billion, serving diversified OEM, laboratory, aerospace, medical, government, and industrial customers. **The business combines mission-critical products, high switching costs, and recurring aftermarket revenue with a disciplined acquisition model.** Q2 2026 sales reached a record $2.04 billion, up 15.0% year over year and approximately $70 million–$90 million above estimates. Adjusted EPS increased 17.4% to $2.09, adjusted operating margin expanded to 26.6%, and management raised full-year 2026 adjusted EPS guidance to $8.20–$8.30 from $7.94–$8.14. Full-year sales are expected to grow approximately 10%. The $5.0 billion Indicor acquisition adds approximately $1.1 billion of annualized sales and recurring aftermarket exposure, but raises leverage to approximately 2.3x EBITDA. At $236.25, AMETEK trades at 28.36x forward P/E on $8.25 midpoint EPS. **The five-year probability-weighted target is $364.59, with integration, synergy realization, and deleveraging as the key catalysts.**